NAS:LUCD Key Ratios
| Market Cap $ M | 192.86 |
| Enterprise Value $ M | 184.36 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 16.83 |
| Price/Sales | 25.87 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 5.00 |
| EPS (TTM) $ | -0.45 |
| Beneish M-Score | -0.89 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -8.30 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -3.53 |
| EV-to-EBITDA | -3.59 |
| PEG | -- |
| Shares Outstanding M | 190.95 |
| Net Margin (%) | -959.76 |
| Operating Margin % | -930.85 |
| Pre-tax Margin (%) | -959.76 |
| Quick Ratio | 1.31 |
| Current Ratio | 1.33 |
| ROA % (ttm) | -127.25 |
| ROE % (ttm) | -438.71 |
| ROIC % (ttm) | -177.22 |
| Dividend Yield % | -- |
| Altman Z-Score | -11.30 |
LUCD Number of Guru Trades
LUCD Volume of Guru Trades
Gurus Latest Trades with NAS:LUCD
NAS:LUCD is held by these investors
Lucid Diagnostics Inc Insider Transactions
Guru Commentaries on NAS:LUCD
Lucid Diagnostics markets an FDA-approved DNA test for early detection of esophageal precancer and cancer, known as EsoGuard. We believe EsoGuard has a multi-billion dollar market opportunity due to its unique capabilities and strong clinical data. The test's patient need is significant, and its clinical utility has been positively validated by independent experts. We are optimistic about the potential for Medicare reimbursement, which could lead to broader commercial adoption and meaningful revenues for Lucid. Despite concerns about dilution and corporate structure, we see substantial upside in the stock given the underappreciation of EsoGuard's value by the market.
News about NAS:LUCD
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
